昂丹司琼在肺癌化疗中的止吐效果

Antiemetic effect of Ondansetron in chemotherapy of lung cancer

目的 观察分析昂丹司琼对肺癌化疗患者所致恶心呕吐反应的临床疗效。方法 选取2012年12月~2014年6月沈阳医学院附属中心医院收治的非小细胞肺癌患者60例,根据随机数字表法将其分为A组和B组,各30例。顺铂联合长春瑞滨化疗方案可以分为两个阶段。第一阶段化疗后A组采用昂丹司琼止吐,B组应用胃复安止吐。第二阶段化疗后A组采用胃复安止吐,B组应用昂丹司琼止吐。昂丹司琼8 mg/次,每日1次,连续2 d静推;胃复安10 mg/次,每日1次,连续2 d口服。观察记录药物疗效及不良反应发生情况。结果 首轮化疗后,A组总有效率（90.0%）显著高于B组（43.3%）,差异有统计学意义（χ2=14.7,P=0.000）,第二轮化疗后,B组总有效率（93.3%）显著高于A组（40.0%）,差异有统计学意义（χ2=19.2,P=0.000）;同时,首轮化疗A组不良反应发生率（23.3%）显著低于B组（53.3%）,差异有统计学意义（χ2=5.711,P=0.017）,第二轮化疗后,B组不良反应发生率（20.0%）显著低于A组（46.7%）,差异有统计学意义（χ2=4.800,P=0.028）。结论 昂丹司琼可以有效减少患者恶心呕吐的发生率,减轻患者化疗期间的痛苦,提高患者的生存质量。由于昂丹司琼的高选择作用,因而不良反应也较少。

Objective To investigate and analyze the clinical effect of Ondansetron for the nausea and vomiting induced by chemotherapy of patients with lung cancer. Methods Sixty patients with non-small cell lung cancer admitted to Central Hospital Affiliated to Shenyang Medical College from December 2012 to June 2014 were selected, and they were divided into group A and group B according to random number table, with 30 cases in each group. The chemotherapy regimens of Cisplatin combined with Vinorelbine could be divided into two phases. After the first phase of chemotherapy, group A was taken Ondansetron to stop vomiting, group B was taken Metoclopramide to stop vomiting. After the second phase of chemotherapy, group A was taken Metoclopramide to stop vomiting, group B was taken On- dansetron to stop vomiting. Ondansetron： every time 8 mg, once a day, intravenous injection for 2 d continuously. Met0- clopramide： every time 10 rag, once a day, oral for 2 d continuously. The drug therapy and conditions of adverse reac- tions were observed and recorded. Results After the first round of chemotherapy, the total effective rate of group A （90.0%） was higher than that of group B （43.3%）, the difference was statistically significant （~2=14.7, P = 0.000）. After the second round of chemotherapy, the total effective rate of group B （93.3%） was higher than that of group A （40.0%）, the difference was statistically significant （X2=19.2, P = 0.000）. After the first round of chemotherapy, the incidence of adverse reactions of group A （23.3%） was significantly lower than that of group B （53.3%）, the difference was statistically significant （X2=5.711, P = 0.017）. After the second round of chemotherapy, the incidence of adverse reactions of group B （20.0%） was lower than that of group A （46.7%）, the difference was statistically significant （~2=4.800, P = 0.028）. Conclusion Ondansetron can effectively reduce the incidence of nausea and vomiting, relieve the suffering of patients during chemotherapy, improve the quality of life of patients. Due to the high selection function of Ondansetron, the adverse reactions are less.